Insider · CIK 0002029985
Srini Tenjarla
Files at SER (Serina Therapeutics, Inc.). First filing -, latest -.
In brief
Srini Tenjarla files SEC Form 4 as officer at SER (Serina Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Srini Tenjarla has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | SER Serina Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +85,558 | $0.00 | $0 | 85,558 | May 26, 2026 |
| Feb 3, 2026 | SER Serina Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +69,000 | $0.00 | $0 | 69,000 | Feb 17, 2026 |
Questions about Srini Tenjarla
Answered from the filings on this page, as of the latest one.
Is Srini Tenjarla buying or selling?
Srini Tenjarla has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Srini Tenjarla's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Srini Tenjarla has 0.
Where does Srini Tenjarla file Form 4?
Srini Tenjarla has filed Form 4 at SER (Serina Therapeutics, Inc.) as SVP, CMC & Formulation. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.